Antiretroviral Therapy Current Events | Antiretroviral Therapy News | 4
|
| Page
4 of
36 |
712 Results |
|
|
|
Sort By:
Page Views | Date |
Waking up dormant HIV
HAART (highly active anti-retroviral therapy) has emerged as an extremely effective HIV treatment that keeps virus levels almost undetectable; however, HAART can never truly eradicate the virus as some HIV always remains dormant in cells. view more (2009-03-17)
HIV in the nervous system - still a cause for concern?
HIV infection can be controlled with antiretroviral drugs, but it cannot be wiped out. New evidence suggests that low levels of HIV may still lead to long-term brain damage and dementia, scientists heard today (Tuesday 09 April 2002) at the spring meeting of the Society for General Microbiology at the University of Warwick. "There is concern for... view more... (2002-04-02)
Cytomegalovirus infection still associated with poor HIV/AIDS prognosis (p 2101, 2116)
Results of a UK study in this week's issue of THE LANCET highlight how the treatment of cytomegalovirus infection remains a priority in order to improve the prognosis for people with HIV-1 infection, including people already receiving antiretroviral therapy. The advent of highly active antiretroviral therapy (HAART) at the end of the 20th century... view more... (2004-06-23)
Socioeconomic Position Associated with Effectiveness of HIV Drugs, Even Among Subjects Adhering to Treatment Schedules
Socioeconomic position is a determinant of antiretroviral treatment effectiveness during initial therapy for HIV-1 infection. view more (2007-09-10)
Efavirenz-Based Initial Therapies Associated with Better Outcomes in HIV-Infected Adults
A study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that HIV-infected patients taking the antiretroviral drug efavirenz were more likely to adhere to treatment and less likely to experience virologic failure and death compared to patients taking nevirapine. view more (2008-10-15)
Maternal HIV-1 treatment protects against transmission to newborns
Mothers receiving highly active antiretroviral therapy (HAART) to treat HIV-1 infection are less likely than untreated mothers to transmit the virus to their newborns through breastfeeding. view more (2009-10-19)
Abacavir Could Play Important Future Role In Treatment Of Children With HIV-1 (p 733)
Results of the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial, published in this week's issue of THE LANCET, suggest an important future role for the drug abacavir in the treatment of children with HIV-1. Antiretroviral HIV-1 drug treatment for adults in more-developed countries usually involves combination therapy with two... view more... (2002-02-28)
Antiretroviral Therapy Effective In Reducing Mother-to-child HIV-1 Transmission When Started After Childbirth (p 1171)
Results of a study from Malawi in this week's issue of THE LANCET highlight how antiretroviral therapy targeted at babies soon after childbirth (because their mothers' HIV diagnosis was made around the time of delivery) is still effective in preventing vertical HIV-1 transmission from mothers to their children. Zidovudine and nevirapine have been... view more... (2003-10-08)
HIV drug maraviroc effective for drug-resistant patients
As many as one quarter of HIV patients have drug resistance, limiting their treatment options and raising their risk for AIDS and death. view more (2008-10-02)
Anti-HIV drugs unlikely to stop HIV spread
Researchers believe antiretroviral therapy (ART) will not be effective in stopping HIV epidemics even if it is made universally available in poorer countries, and that widespread use could even lead to an increase in the numbers infected with HIV. view more (2006-03-14)
Model of pre-exposure prophylaxis against HIV forecasts benefits, potential cost-effectiveness
For every two people who begin treatment for HIV infection globally, five others become newly infected. Therefore, preventing new HIV infections is the foremost strategy for ending the HIV/AIDS epidemic. view more (2009-02-10)
Having a stable partner delays AIDS in HIV patients
For people with HIV, having a stable partner is associated with slower rate of progression to AIDS or death, finds a study in this week's BMJ. Researchers in Switzerland followed 3,736 adults with HIV who had started highly active antiretroviral therapy (HAART) before 2002. Every six months, patients were asked whether they had had sexual... view more... (2004-01-03)
IL-2 immunotherapy fails to benefit HIV-infected individuals already taking antiretrovirals
Providing a synthetic form of the immune system protein interleukin-2 (IL-2) to HIV-infected individuals already taking combination antiretroviral therapy boosts their numbers of CD4+ T cells, the key white blood cells destroyed by HIV, but fails to reduce their risk of HIV-associated opportunistic diseases or death compared with combination... view more... (2009-02-11)
Study sets new gold standard for initial antiretroviral treatment of HIV infection
An international team of AIDS researchers at Johns Hopkins and other institutions has found that a once-daily combination of three antiretroviral drugs works better as an initial treatment for HIV infection than another three-drug combination long considered the gold standard. view more (2006-01-19)
Update on tuberculosis - 2005
A reduction in tuberculosis (TB) incidence, prevalence and death rate can be achieved by 2015 in most parts of the world, with the greatest challenges occurring in Africa and Eastern Europe, according to a projection by the Stop TB Department of the World Health Organization. view more (2006-03-01)
Exciting Development in Anti-Retroviral Drug Discovery Made at Oxford
Researchers in Oxford University's Sir William Dunn School of Pathology have developed a novel HTS for identifying antiretroviral (HIV) agents/drugs that inhibit HIV infectivity. Current anti-viral drugs prolong the quality of life for many HIV-1+ individuals, but they do not stop the virus from infecting new cells. Since these drugs mostly... view more... (2003-06-05)
International HIV/AIDS trial finds risks increase on episodic antiretroviral therapy
Results from one of the largest HIV/AIDS treatment trials ever conducted show that a specific strategy of interrupting antiretroviral therapy more than doubles the risk of AIDS or death from any cause. view more (2006-11-30)
Taking medicine for HIV proves hard to swallow for many people
Highly active antiretroviral therapy has increased the longevity and quality of life for people living with human immunodeficiency virus. But it requires strict adherence in taking the medicine, something that is extremely difficult for many individuals to do. view more (2009-10-23)
Press release ANRS, INSERM, AFSSAPS
Adverse events that were unknown so far, have recently been observed in France in children who had been exposed to antiretroviral drugs (nucleosidic inhibitors of the reverse transcriptase) during intra uterine life and postnatally to prevent mother to child transmission of HIV. The children suffer from mitochondrial dysfunctions. The mitochondry... view more... (1999-06-25)
Asthma risk increases in children treated for HIV
Children whose immune systems rebound after treatment with potent anti-viral drugs for HIV infection face an increased risk of developing asthma, said a federally funded consortium of researchers led by those from Baylor College of Medicine in a report that appears online in the Journal of Allergy and Clinical Immunology. view more (2008-07-02)
|
|
| Page
4 of
36 |
712 Results |
|
|
|
Sort By:
Page Views | Date |
|
